The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 14(4), 179–183 (2007).
  MedlineGoogle Scholar
• 2 International Diabetes Federation. IDF Diabetes Atlas (6th Edition) (2014). www.idf.org/diabetesatlas.
  Google Scholar
• 3 Bourne RR, Stevens GA, White RA et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob. Health 1(6), e339–e349 (2013).
  MedlineGoogle Scholar
• 4 Sanchez-Thorin JC. The epidemiology of diabetes mellitus and diabetic retinopathy. Int. Ophthalmol. Clin. 38(2), 11–18 (1998).
  Medline CASGoogle Scholar
• 5 Agarwal A, Sarwar S, Sepah YJ, Nguyen QD. What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era? Curr. Opin. Ophthalmol. 26(3), 177–183 (2015). •• Summarizes various learning lessons in the management of diabetic macular edema based on level I evidence from a number of multicenter, randomized clinical trials.
  MedlineGoogle Scholar
• 6 Nguyen QD, Brown DM, Marcus DM et al. Ranibizumab for diabetic macular edema: results from 2 Phase III randomized trials: RISE and RIDE. Ophthalmology 119(4), 789–801 (2012). •• This is a landmark trial that provided evidence of the safety and efficacy of ranibizumab in the treatment of diabetic macular edema.
  MedlineGoogle Scholar
• 7 El-Shazly SF, El-Bradey MH, Tameesh MK. Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti-vascular endothelial growth factor treatment outcomes. Clin. Experiment Ophthalmol. 42(4), 369–378 (2014).
  MedlineGoogle Scholar
• 8 Samiy N. Gene therapy for retinal diseases. J. Ophthalmic Vis. Res. 9(4), 506–509 (2014).
  MedlineGoogle Scholar
• 9 Thompson DA, Ali RR, Banin E et al. Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the monaciano symposium. Invest. Ophthalmol. Vis. Sci. 56(2), 918–931 (2015).
  Medline CASGoogle Scholar
• 10 Agarwal A, Soliman MK, Sepah YJ, Do DV, Nguyen QD. Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics. Pharmacogenomics Pers. Med. 7, 399–409 (2014).
  Medline CASGoogle Scholar
• 11 Simo-Servat O, Hernandez C, Simo R. Genetics in diabetic retinopathy: current concepts and new insights. Curr. Genomics 14(5), 289–299 (2013).
  Medline CASGoogle Scholar
• 12 Radha V, Rema M, Mohan V. Genes and diabetic retinopathy. Indian J. Ophthalmol. 50(1), 5–11 (2002).
  MedlineGoogle Scholar
• 13 Khazaee MH, Tavakol Afshari J, Khazaee B et al. HLA-DQB1 subtypes predict diabetic retinopathy in patients with type I diabetes mellitus. Eur. J. Ophthalmol. 19(4), 638–645 (2009).
  MedlineGoogle Scholar
• 14 Kastelan S, Tomic M, Salopek-Rabatic J et al. The association between the HLA system and retinopathy development in patients with Type 1 diabetes mellitus. Coll. Antropol. 37(Suppl. 1), 65–70 (2013).
  Medline CASGoogle Scholar
• 15 Lipner EM, Tomer Y, Noble JA et al. HLA class I and II alleles are associated with microvascular complications of Type 1 diabetes. Hum. Immunol. 74(5), 538–544 (2013).
  Medline CASGoogle Scholar
• 16 Sia C, Weinem M. The role of HLA class I gene variation in autoimmune diabetes. Rev. Diabet. Stud. 2(2), 97–109 (2005).
  MedlineGoogle Scholar
• 17 Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 58(9), 2137–2147 (2009).
  Medline CASGoogle Scholar
• 18 Cheema BS, Kohli HS, Sharma R, Bhansali A, Khullar M. Endothelial nitric oxide synthase gene polymorphism and Type 2 diabetic retinopathy among Asian Indians. Acta Diabetol. 49(6), 481–488 (2012).
  Medline CASGoogle Scholar
• 19 Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the rage gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50(6), 1505–1511 (2001).
  Medline CASGoogle Scholar
• 20 Tong Z, Yang Z, Patel S et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc. Natl Acad. Sci. USA 105(19), 6998–7003 (2008).
  Medline CASGoogle Scholar
• 21 Dyer KH, Silva PS, Sun JK. Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy. Semin. Ophthalmol. 28(5–6), 347–354 (2013).
  MedlineGoogle Scholar
• 22 Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93(8), 1493–1495 (1996).
  Medline CASGoogle Scholar
• 23 Brogan IJ, Khan N, Isaac K et al. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum. Immunol. 60(12), 1245–1249 (1999).
  Medline CASGoogle Scholar
• 24 Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 63(4), 812–816 (2003).
  Medline CASGoogle Scholar
• 25 Han L, Zhang L, Xing W et al. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case-control studies. J. Diabetes Res. 2014, 805801 (2014).
  MedlineGoogle Scholar
• 26 Petrovic MG, Korosec P, Kosnik M et al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol. Vis. 14, 1382–1387 (2008).
  Medline CASGoogle Scholar
• 27 Awata T, Kurihara S, Takata N et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in Type 2 diabetes. Biochem. Biophys. Res. Commun. 333(3), 679–685 (2005).
  Medline CASGoogle Scholar
• 28 Wang H, Cheng JW, Zhu LS et al. Meta-analysis of association between the -2578C/A polymorphism of the vascular endothelial growth factor and retinopathy in Type 2 diabetes in Asians and Caucasians. Ophthalmic Res. 52(1), 1–8 (2014).
  MedlineGoogle Scholar
• 29 Liu L, Jiao J, Wang Y et al. TGF-β1 gene polymorphism in association with diabetic retinopathy susceptibility: a systematic review and meta-analysis. PLoS ONE 9(4), e94160 (2014).
  MedlineGoogle Scholar
• 30 Grassi MA, Tikhomirov A, Ramalingam S et al. Replication analysis for severe diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 53(4), 2377–2381 (2012).
  MedlineGoogle Scholar
• 31 Cho H, Sobrin L. Genetics of diabetic retinopathy. Curr. Diab. Rep. 14(8), 515 (2014). • Summarizes the key factors involved in the heretability of diabetic retinopathy and genetic polymorphisms associated with severe disease.
  MedlineGoogle Scholar
• 32 Visscher PM, Brown MA, Mccarthy MI, Yang J. Five years of GWAS discovery. Am. J. Hum. Genet. 90(1), 7–24 (2012).
  Medline CASGoogle Scholar
• 33 Fu YP, Hallman DM, Gonzalez VH et al. Identification of diabetic retinopathy genes through a genome-wide association study among Mexican–Americans from Starr County, Texas. J. Ophthalmol. doi:10.1155/2010/861291 (2010) (Epub ahead of print).
  MedlineGoogle Scholar
• 34 Grassi MA, Tikhomirov A, Ramalingam S et al. Genome-wide meta-analysis for severe diabetic retinopathy. Hum. Mol. Genet. 20(12), 2472–2481 (2011). • This meta-analysis provides information on several novel genetic loci associated with the pathophysiology of diabetic retinopathy based on evidence from genome-wide association studies.
  Medline CASGoogle Scholar
• 35 Huang YC, Lin JM, Lin HJ et al. Genome-wide association study of diabetic retinopathy in a taiwanese population. Ophthalmology 118(4), 642–648 (2011).
  MedlineGoogle Scholar
• 36 Sheu WH, Kuo JZ, Lee IT et al. Genome-wide association study in a chinese population with diabetic retinopathy. Hum. Mol. Genet. 22(15), 3165–3173 (2013).
  Medline CASGoogle Scholar
• 37 Awata T, Yamashita H, Kurihara S et al. A genome-wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non-coding RNA. PLoS ONE 9(11), e111715 (2014).
  MedlineGoogle Scholar
• 38 Huang LZ, Li YJ, Xie XF et al. Whole-exome sequencing implicates UBE3D in age-related macular degeneration in east asian populations. Nat. Commun. 6, 6687 (2015).
  Medline CASGoogle Scholar
• 39 Aboobakar IF, Allingham RR. Developments in ocular genetics: 2013 annual review. Asia Pac. J. Ophthalmol. (Phila.) 3(3), 181–193 (2014).
  Medline CASGoogle Scholar
• 40 Liang S, Pan M, Hu N et al. Association of angiotensin-converting enzyme gene 2350 G/A polymorphism with diabetic retinopathy in chinese han population. Mol. Biol. Rep. 40(1), 463–468 (2013).
  Medline CASGoogle Scholar
• 41 Manea SA, Robciuc A, Guja C, Heltianu C. Identification of gene variants in NOS3, ET-1 and RAS that confer risk and protection against microangiopathy in Type 2 diabetic obese subjects. Biochem. Biophys. Res. Commun. 407(3), 486–490 (2011).
  Medline CASGoogle Scholar
• 42 Dos Santos KG, Canani LH, Gross JL et al. The -106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian–Brazilians with Type 2 diabetes. Mol. Genet. Metabol. 88(3), 280–284 (2006).
  MedlineGoogle Scholar
• 43 Wang J, Yang MM, Li YB et al. Association of CFH and CFB gene polymorphisms with retinopathy in Type 2 diabetic patients. Mediators Inflamm. 2013, 748435 (2013).
  MedlineGoogle Scholar
• 44 Chen M, Lin WR, Lu CH et al. Chimerin 2 genetic polymorphisms are associated with non-proliferative diabetic retinopathy in taiwanese Type 2 diabetic patients. J. Diabetes Complications 28(4), 460–463 (2014).
  MedlineGoogle Scholar
• 45 Arndt C, Leclercq I, Nazeyrollas P et al. Association of endothelial lipase Thr111IIe polymorphism with proliferative retinopathy in Type 2 diabetes patients. Diabetes Metab. 40(6), 452–458 (2014).
  Medline CASGoogle Scholar
• 46 Taverna MJ, Sola A, Guyot-Argenton C et al. eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy. Diabet. Med. 19(3), 240–245 (2002).
  Medline CASGoogle Scholar
• 47 Abhary S, Burdon KP, Casson RJ et al. Association between erythropoietin gene polymorphisms and diabetic retinopathy. Arch. Ophthalmol. 128(1), 102–106 (2010).
  Medline CASGoogle Scholar
• 48 Katakami N, Matsuhisa M, Kaneto H et al. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for diabetic retinopathy in Japanese patients with Type 2 diabetes. Diabetes Res. Clin. Pract. 89(1), e9–e12 (2010).
  Medline CASGoogle Scholar
• 49 Yigit S, Karakus N, Inanir A. Association of MTHFR gene C677T mutation with diabetic peripheral neuropathy and diabetic retinopathy. Mol. Vis. 19, 1626–1630 (2013).
  Medline CASGoogle Scholar
• 50 Maeda M, Yamamoto I, Fukuda M et al. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese Type 2 diabetic patients. J. Diabetes Complications 22(2), 119–125 (2008).
  MedlineGoogle Scholar
• 51 Sun J, Xu Y, Zhu Y, Lu H. Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in chinese Type 2 diabetic patients. Diabetes Res. Clin. Pract. 64(3), 185–190 (2004).
  Medline CASGoogle Scholar
• 52 Mankoc Ramus S, Kumse T, Globocnik Petrovic M, Petrovic D, Cilensek I. Snp rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in slovenian patients with Type 2 diabetes. Biomed Res. Int. 2013, 364073 (2013).
  MedlineGoogle Scholar
• 53 Ng ZX, Kuppusamy UR, Iqbal T, Chua KH. Receptor for advanced glycation end-product (RAGE) gene polymorphism 2245G/A is associated with pro-inflammatory, oxidative-glycation markers and sRAGE in diabetic retinopathy. Gene 521(2), 227–233 (2013).
  Medline CASGoogle Scholar
• 54 Zhang HM, Chen LL, Wang L et al. Association of 1704G/T and G82S polymorphisms in the receptor for advanced glycation end products gene with diabetic retinopathy in chinese population. J. Endocrinol. Invest. 32(3), 258–262 (2009).
  Medline CASGoogle Scholar
• 55 Sobrin L, Green T, Sim X et al. Candidate gene association study for diabetic retinopathy in persons with Type 2 diabetes: the candidate gene association resource (CARE). Invest. Ophthalmol. Vis. Sci. 52(10), 7593–7602 (2011).
  Medline CASGoogle Scholar
• 56 Bandello F, Casalino G, Loewenstein A et al. Pharmacological approach to diabetic macular edema. Ophthalmic Res. 51(2), 88–95 (2014).
  Medline CASGoogle Scholar
• 57 Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther. Adv. Endocrinol. Metab. 4(6), 151–169 (2013).
  Medline CASGoogle Scholar
• 58 Patelli F, Radice P, Giacomotti E. Diabetic macular edema. Dev. Ophthalmol. 54, 164–173 (2014).
  MedlineGoogle Scholar
• 59 Rajendram R, Fraser-Bell S, Kaines A et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch. Ophthalmol. 130(8), 972–979 (2012). •• This multicenter clinical trial compares the efficacy of intravitreal bevacizumab and macular laser therapy in the management of eyes with diabetic macular edema.
  Medline CASGoogle Scholar
• 60 Do DV, Schmidt-Erfurth U, Gonzalez VH et al. The DA VINCI study: Phase 2 primary results of VEGF Trap-eye in patients with diabetic macular edema. Ophthalmology 118(9), 1819–1826 (2011). •• This landmark multicenter trial studied the efficacy of different dosing regimens of intravitreal aflibercept compared with macular laser therapy in the treatment of diabetic macular edema.
  MedlineGoogle Scholar
• 61 Jain RK, Duda DG, Willett CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6(6), 327–338 (2009).
  Medline CASGoogle Scholar
• 62 Wykoff CC, Brown DM, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br. J. Ophthalmol. 98(7), 951–955 (2014).
  MedlineGoogle Scholar
• 63 Dabir SS, Das D, Nallathambi J, Mangalesh S, Yadav NK, Schouten JS. Differential systemic gene expression profile in patients with diabetic macular edema: responders versus nonresponders to standard treatment. Indian J. Ophthalmol. 62(1), 66–73 (2014). • This prospective study analyzed altered gene expression patterns in patients using microarray technique, providing insights into the possible signaling pathways associated with diabetic retinopathy.
  MedlineGoogle Scholar
• 64 Choudhuri S, Chowdhury IH, Das S et al. Role of NF-κB activation and VEGF gene polymorphisms in VEGF up regulation in non-proliferative and proliferative diabetic retinopathy. Mol. Cell. Biochem. 405(1–2), 265–279 (2015).
  Medline CASGoogle Scholar
• 65 Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles. Exp. Eye Res. 82(5), 798–806 (2006).
  Medline CASGoogle Scholar
• 66 Yang H, Huang Y, Chen X et al. The role of CTGF in the diabetic rat retina and its relationship with VEGF and TGF-β(2), elucidated by treatment with CTGFsiRNA. Acta Ophthalmol. 88(6), 652–659 (2010).
  Medline CASGoogle Scholar
• 67 Yang Y, Yang K, Li Y et al. Decursin inhibited proliferation and angiogenesis of endothelial cells to suppress diabetic retinopathy via VEGFR2. Mol. Cell. Endocrin. 378(1–2), 46–52 (2013).
  Medline CASGoogle Scholar
• 68 Adhi M, Cashman SM, Kumar-Singh R. Adeno-associated virus mediated delivery of a non-membrane targeted human soluble CD59 attenuates some aspects of diabetic retinopathy in mice. PLoS ONE 8(10), e79661 (2013).
  Medline CASGoogle Scholar
• 69 Meneses PI, Hajjar KA, Berns KI, Duvoisin RM. Recombinant angiostatin prevents retinal neovascularization in a murine proliferative retinopathy model. Gene therapy 8(8), 646–648 (2001).
  Medline CASGoogle Scholar
• 70 Spranger J, Hammes HP, Preissner KT, Schatz H, Pfeiffer AF. Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation. Diabetologia 43(11), 1404–1407 (2000).
  Medline CASGoogle Scholar
• 71 Noma H, Funatsu H, Yamashita H et al. Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin. Arch. Ophthalmol. 120(8), 1075–1080 (2002).
  Medline CASGoogle Scholar
• 72 Funatsu H, Yamashita H, Noma H et al. Stimulation and inhibition of angiogenesis in diabetic retinopathy. Jpn. J. Ophthalmol. 45(6), 577–584 (2001).
  Medline CASGoogle Scholar
• 73 Gao G, Shao C, Zhang SX, Dudley A, Fant J, Ma JX. Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia 46(5), 689–698 (2003).
  Medline CASGoogle Scholar
• 74 Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 44(6), 757–765 (2001).
  Medline CASGoogle Scholar
• 75 Shibuya M. VEGF-VEGFR signals in health and disease. Biomol. Ther. (Seoul) 22(1), 1–9 (2014).
  Medline CASGoogle Scholar
• 76 Min Z, Qiang W, Benwen S, Bin L, Xinhua D. Lentivirus-mediated sFlt-1 gene fragment transfer suppresses retinal neovascularization. Curr. Eye Res. 34(5), 401–410 (2009).
  MedlineGoogle Scholar
• 77 Lamartina S, Cimino M, Roscilli G et al. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy. J. Gene Med. 9(10), 862–874 (2007).
  Medline CASGoogle Scholar
• 78 Bainbridge JW, Mistry A, De Alwis M et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther. 9(5), 320–326 (2002). •• Demonstrated a novel technique of in vivo VEGF inhibition using adeno-associated virus vector transfer of sFlt-1 gene.
  Medline CASGoogle Scholar
• 79 Dhaunsi GS, Yousif MH, Akhtar S et al. Angiotensin-(1–7) prevents diabetes-induced attenuation in PPAR-γ and catalase activities. Eur. J. Pharmacol. 638(1–3), 108–114 (2010).
  Medline CASGoogle Scholar
• 80 Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol. Sci. 29(7), 367–374 (2008).
  Medline CASGoogle Scholar
• 81 Ruiz-Ortega M, Lorenzo O, Ruperez M et al. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 38(6), 1382–1387 (2001).
  Medline CASGoogle Scholar
• 82 Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 38(3 Pt 2), 635–638 (2001).
  Medline CASGoogle Scholar
• 83 Chaturvedi N, Porta M, Klein R et al. Effect of candesartan on prevention (direct-prevent 1) and progression (direct-protect 1) of retinopathy in Type 1 diabetes: randomised, placebo-controlled trials. Lancet 372(9647), 1394–1402 (2008).
  Medline CASGoogle Scholar
• 84 Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with Type 1 diabetes. The euclid study group. Eurodiab controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet 351(9095), 28–31 (1998).
  Medline CASGoogle Scholar
• 85 Sjolie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in Type 2 diabetes (direct-protect 2): a randomised placebo-controlled trial. Lancet 372(9647), 1385–1393 (2008).
  MedlineGoogle Scholar
• 86 Li Q, Verma A, Zhu P et al. Gene therapy for diabetic retinopathy – targeting the renin-angiotensin system (2013). http://cdn.intechopen.com/pdfs-wm/43280.pdf.
  Google Scholar
• 87 El-Bab MF, Zaki NS, Mojaddidi MA, Al-Barry M, El-Beshbishy HA. Diabetic retinopathy is associated with oxidative stress and mitigation of gene expression of antioxidant enzymes. Int. J. Gen. Med. 6, 799–806 (2013).
  MedlineGoogle Scholar
• 88 Kowluru RA, Kowluru V, Xiong Y, Ho YS. Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radic. Biol. Med. 41(8), 1191–1196 (2006).
  Medline CASGoogle Scholar
• 89 Kowluru RA, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 53(12), 3233–3238 (2004).
  Medline CASGoogle Scholar
• 90 Kanwar M, Chan PS, Kern TS, Kowluru RA. Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Invest. Ophthalmol. Vis. Sci. 48(8), 3805–3811 (2007). • Provided early evidence of the role of epigenetics in the pathogenesis of diabetic retinopathy and the role of a mitochondrial enzyme, superoxide dismutase.
  MedlineGoogle Scholar
• 91 Zhang L, Xia H, Han Q, Chen B. Effects of antioxidant gene therapy on the development of diabetic retinopathy and the metabolic memory phenomenon. Graefes Arch. Clin. Exp. Ophthalmol. 253(2), 249–259 (2015).
  Medline CASGoogle Scholar
• 92 Liu Y, Tang L, Chen B. Effects of antioxidant gene therapy on retinal neurons and oxidative stress in a model of retinal ischemia/reperfusion. Free Radic. Biol. Med. 52(5), 909–915 (2012).
  Medline CASGoogle Scholar
• 93 Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. Invest. Ophthalmol. Vis. Sci. 41(13), 4195–4202 (2000).
  Medline CASGoogle Scholar
• 94 Gerl VB, Bohl J, Pitz S et al. Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 43(4), 1104–1108 (2002).
  MedlineGoogle Scholar
• 95 Zhang J, Gerhardinger C, Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 51(12), 3499–3504 (2002).
  Medline CASGoogle Scholar
• 96 Lai CM, Estcourt MJ, Himbeck RP et al. Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther. 19(10), 999–1009 (2012).
  Medline CASGoogle Scholar
• 97 Mao Y, Kiss S, Boyer JL et al. Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab. Hum. Gene Ther. 22(12), 1525–1535 (2011). •• Describes a novel therapeutic strategy of long-term in vivo VEGF inhibition using intraocular administration of bevacizumab-expressing gene.
  Medline CASGoogle Scholar
• 98 Ramirez M, Wu Z, Moreno-Carranza B et al. Vasoinhibin gene transfer by adenoassociated virus Type 2 protects against VEGF- and diabetes-induced retinal vasopermeability. Invest. Ophthalmol. Vis. Sci. 52(12), 8944–8950 (2011).
  MedlineGoogle Scholar
• 99 Verma A, Shan Z, Lei B et al. ACE2 and ANG-(1–7) confer protection against development of diabetic retinopathy. Mol. Ther. 20(1), 28–36 (2012).
  Medline CASGoogle Scholar
• 100 Ildefonso CJ, Jaime H, Rahman MM et al. Gene delivery of a viral anti-inflammatory protein to combat ocular inflammation. Hum. Gene Ther. 26(1), 59–68 (2015).
  Medline CASGoogle Scholar
• 101 Biswal MR, Prentice HM, Dorey CK, Blanks JC. A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 55(12), 8044–8053 (2014).
  Medline CASGoogle Scholar
• 102 Shyong MP, Lee FL, Kuo PC et al. Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. Mol. Vis. 13, 133–141 (2007).
  Medline CASGoogle Scholar
• 103 Haurigot V, Villacampa P, Ribera A et al. Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy. PLoS ONE 7(7), e41511 (2012).
  Medline CASGoogle Scholar
• 104 Yu H, Chen L, Jiang J. Administration of pigment epithelium-derived factor delivered by adeno-associated virus inhibits blood-retinal barrier breakdown in diabetic rats. Mol. Vis. 16, 2384–2394 (2010).
  Medline CASGoogle Scholar
• 105 Gong Y, Chang ZP, Ren RT et al. Protective effects of adeno-associated virus mediated brain-derived neurotrophic factor expression on retinal ganglion cells in diabetic rats. Cell. Mol. Neurobiol. doi: 10.1007/s10571-011-9779-x (2012).
  Google Scholar
• 106 Li B, Zhang HQ, Shi Y et al. Overexpression of nuclear transport factor 2 may protect against diabetic retinopathy. Mol. Vis. 15, 861–869 (2009).
  Medline CASGoogle Scholar
• 107 Kowluru RA, Mishra M. Contribution of epigenetics in diabetic retinopathy. Sci. China Life Sci. 58(6), 556–63 (2015).
  Medline CASGoogle Scholar
• 108 Kowluru RA, Santos JM, Mishra M. Epigenetic modifications and diabetic retinopathy. Biomed Res. Int. 2013, 635284 (2013).
  MedlineGoogle Scholar
• 109 Zhong Q, Kowluru RA. Epigenetic modification of SOD2 in the development of diabetic retinopathy and in the metabolic memory: role of histone methylation. Invest. Ophthalmol. Vis. Sci. 54(1), 244–250 (2013).
  Medline CASGoogle Scholar
• 110 Zhong Q, Kowluru RA. Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. Diabetes 62(7), 2559–2568 (2013).
  Medline CASGoogle Scholar
• 111 Zhong Q, Kowluru RA. Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon. J. Cell. Biochem. 110(6), 1306–1313 (2010).
  Medline CASGoogle Scholar
• 112 Mastropasqua R, Toto L, Cipollone F et al. Role of microRNAs in the modulation of diabetic retinopathy. Prog. Retin. Eye Res. 43, 92–107 (2014).
  Medline CASGoogle Scholar
• 113 Kato M, Castro NE, Natarajan R. Micrornas: potential mediators and biomarkers of diabetic complications. Free Radic. Biol. Med. 64, 85–94 (2013).
  Medline CASGoogle Scholar
• 114 Silva VA, Polesskaya A, Sousa TA et al. Expression and cellular localization of microRNA-29b and RAX, an activator of the RNA-dependent protein kinase (PKR), in the retina of streptozotocin-induced diabetic rats. Mol. Vis. 17, 2228–2240 (2011).
  Medline CASGoogle Scholar
• 115 Al-Kateb H, Boright AP, Mirea L et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes 57(1), 218–228 (2008).
  Medline CASGoogle Scholar
• 116 Boright AP, Paterson AD, Mirea L et al. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in Type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 54(4), 1238–1244 (2005).
  Medline CASGoogle Scholar
• 117 Hosseini SM, Boright AP, Sun L et al. The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy. Hum. Genet. 134(2), 247–257 (2015).
  Medline CASGoogle Scholar
• 118 Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 – an update. J. Gene Med. 15(2), 65–77 (2013). • Provides a comprehensive overview of progress being made in the clinical trials using gene therapy worldwide.
  Medline CASGoogle Scholar
• 119 Vandenberghe LH. What is next for retinal gene therapy? Cold Spring Harb. Perspect. Med. 5(10), a017442 (2015).
  MedlineGoogle Scholar